Navigation Links
GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
Date:7/5/2011

RESEARCH TRIANGLE PARK, N.C., July 5, 2011 /PRNewswire/ -- GlaxoSmithKline (NYSE: GSK) today announced that it has implemented the next phase of its new incentive compensation program for professional sales representatives with the introduction of a new performance evaluation methodology and process.  

In January 2011, GSK eliminated individual sales goals as part of the company's incentive compensation program for sales professionals who work directly with healthcare professionals.  Beginning July 1, GSK is putting in place a new method for evaluating sales professionals' performance and bonus in alignment with the company's values of transparency, respect for people, integrity and focus on the patient.  

Under the new system, GSK's sales professionals who work directly with healthcare providers will continue to be compensated with a competitive mix of salary and bonus.  In place of individual sales targets, three primary factors will be evaluated to assess performance and determine bonuses: selling competency, customer evaluations, and the overall performance of their business unit.

"Our sales professionals play a critical role in providing doctors with appropriate, updated information on the safety and benefits of our medicines.  This information helps doctors make informed treatment decisions for their patients," said Deirdre Connelly, President, North America Pharmaceuticals, GlaxoSmithKline. "This industry-leading incentive program aligns our performance measures and rewards with our values so doctors can be confident that our sales professionals are focused on improving patient health."

Since first announcing its plans in July 2010 to radically change its sales incentive compensation system, GSK has conducted extensive research to define how best to obtain robust, ongoing, unbiased assessments of the effectiveness of its sales professionals in meeting customer needs. This effort is part of a wider evolution to align the company's sales and marketing programs with societal and customer expectations.

"Along with changing many aspects of how we conduct our business, we have also invested heavily in training and compliance programs to ensure that we are operating at or above the pharmaceutical industry code of ethics," Connelly said.

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information go to us.gsk.com, follow us on twitter.com/GSKUS or visit our blog (www.morethanmedicine.us.gsk.com/blog/).

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2010.


'/>"/>
SOURCE GlaxoSmithKline
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
2. GlaxoSmithKline Accelerates Review of Exelixis XL880
3. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
4. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
5. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
6. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
7. GlaxoSmithKline Reports Further Progress of Oncology Portfolio
8. GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
9. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
10. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
11. Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017 Wound care devices and products ... the wound. The industry mainly consists of establishments engaged ... treatment of wounds caused by mechanical, chemical, thermal, and ... such as diabetes, skin related diseases, immunological diseases, and ... was the largest region in the wound care ...
(Date:3/29/2017)... Mar. 29, 2017 Research and Markets has ... report to their offering. ... The global gas chromatograph market to grow at ... The report, Global Gas Chromatograph Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:3/29/2017)... DIEGO , March 29, 2017 Avelas Biosciences, Inc., ... from diagnosis through treatment, today announced that Carmine N. Stengone ... the company at the Needham & Company 16 th Annual ... (8:20 a.m. PDT) at the Westin Grand Central Hotel in ... ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional Squash ... has enlisted New York City-based sports and entertainment marketing firm Leverage Agency as ... opportunities for the Professional Squash Association (PSA), which includes first-time ever title sponsorship, ...
(Date:3/29/2017)... ... ... Sublime Naturals and its founder, Kathy Heshelow, are big fans of Turmeric. ... for thousands of years. , "The West has caught on, and has discovered Turmeric, ... Use it For Your Wellness. Overcome Inflammation, Enemy of the Body. " The ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based on research from ... employers face in trying to balance both short-term and long-term benefits demands. ... to the growing complexity, companies are finding that the short-term strategies used to ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... documenting and diagramming network and data center assets and audio-video devices has recently ... request new equipment shapes for free and download shapes and stencils from ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of ... and is touted to be the next revolution in our fight against this complex ... the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While ...
Breaking Medicine News(10 mins):